<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>First Trust Germany Alphadex® Fund — News on 6ix</title>
<link>https://6ix.com/company/first-trust-germany-alphadexr-fund</link>
<description>Latest news and press releases for First Trust Germany Alphadex® Fund on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 13 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/first-trust-germany-alphadexr-fund" rel="self" type="application/rss+xml" />
<item>
<title>Nevada Organic Phosphate Announces Feature in BTV Broadcast</title>
<link>https://6ix.com/company/first-trust-germany-alphadexr-fund/news/nevada-organic-phosphate-announces-feature-in-btv-broadcast-37</link>
<guid isPermaLink="true">https://6ix.com/company/first-trust-germany-alphadexr-fund/news/nevada-organic-phosphate-announces-feature-in-btv-broadcast-37</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - March 13, 2026) - Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) ("NOP" or the "Company"), a B.C.</description>
</item>
<item>
<title>Equillium Announces $35 Million Financing with RA Capital Management</title>
<link>https://6ix.com/company/first-trust-germany-alphadexr-fund/news/equillium-announces-dollar35-million-financing-with-ra-capital-management-20</link>
<guid isPermaLink="true">https://6ix.com/company/first-trust-germany-alphadexr-fund/news/equillium-announces-dollar35-million-financing-with-ra-capital-management-20</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Capital strengthens the advancement of EQ504 through key clinical milestones Anticipated net proceeds, along with existing cash and cash equivalents, expected</description>
</item>
<item>
<title>Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum</title>
<link>https://6ix.com/company/first-trust-germany-alphadexr-fund/news/alto-neuroscience-announces-participation-at-the-stifel-2026-virtual-cns-forum-11</link>
<guid isPermaLink="true">https://6ix.com/company/first-trust-germany-alphadexr-fund/news/alto-neuroscience-announces-participation-at-the-stifel-2026-virtual-cns-forum-11</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development</description>
</item>
<item>
<title>UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence</title>
<link>https://6ix.com/company/first-trust-germany-alphadexr-fund/news/urogen-applauds-bcans-new-faces-of-bladder-cancer-report-highlighting-recurrence-burden-and-fear-of-recurrence-38</link>
<guid isPermaLink="true">https://6ix.com/company/first-trust-germany-alphadexr-fund/news/urogen-applauds-bcans-new-faces-of-bladder-cancer-report-highlighting-recurrence-burden-and-fear-of-recurrence-38</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>National survey of more than 1,100 bladder cancer patients finds nearly 80% report fear of recurrence, rising above 90% among patients under 50Many</description>
</item>
<item>
<title>SunPower Completes the Integration of Sunder Energy</title>
<link>https://6ix.com/company/first-trust-germany-alphadexr-fund/news/sunpower-completes-the-integration-of-sunder-energy-26</link>
<guid isPermaLink="true">https://6ix.com/company/first-trust-germany-alphadexr-fund/news/sunpower-completes-the-integration-of-sunder-energy-26</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Integration Strengthens New Engine of Growth, Quality Standards, and Gains U.S. No 4 Spot OREM, Utah, March 13, 2026 (GLOBE NEWSWIRE) -- SunPower Inc.</description>
</item>
<item>
<title>U.S. Energy Corp. Reports 2025 Results and Highlights Transformation into Integrated Industrial Gas, Energy, and Carbon Management Platform</title>
<link>https://6ix.com/company/first-trust-germany-alphadexr-fund/news/us-energy-corp-reports-2025-results-and-highlights-transformation-into-integrated-industrial-gas-energy-and-carbon-management-platform-10</link>
<guid isPermaLink="true">https://6ix.com/company/first-trust-germany-alphadexr-fund/news/us-energy-corp-reports-2025-results-and-highlights-transformation-into-integrated-industrial-gas-energy-and-carbon-management-platform-10</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>HOUSTON, March 13, 2026 (GLOBE NEWSWIRE) -- U.S. Energy Corporation (NASDAQ: USEG, "U.S. Energy" or the "Company") today reported financial and operating</description>
</item>
<item>
<title>Xtra-Gold Announces 2026 Normal Course Issuer Bid and Results of 2025 Bid</title>
<link>https://6ix.com/company/first-trust-germany-alphadexr-fund/news/xtra-gold-announces-2026-normal-course-issuer-bid-and-results-of-2025-bid-50</link>
<guid isPermaLink="true">https://6ix.com/company/first-trust-germany-alphadexr-fund/news/xtra-gold-announces-2026-normal-course-issuer-bid-and-results-of-2025-bid-50</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - March 13, 2026) - Xtra-Gold Resources Corp. (TSX: XTG) (OTCQB: XTGRF) ("Xtra- Gold" or the "Company") is pleased to</description>
</item>
<item>
<title>Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/first-trust-germany-alphadexr-fund/news/savara-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-business-update-5</link>
<guid isPermaLink="true">https://6ix.com/company/first-trust-germany-alphadexr-fund/news/savara-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-business-update-5</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Achieved Regulatory Milestones for the MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Development Program: U.S. Food and Drug</description>
</item>
<item>
<title>Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company</title>
<link>https://6ix.com/company/first-trust-germany-alphadexr-fund/news/lifeward-receives-shareholder-approval-to-close-on-strategic-partnership-with-oramedcreating-diversified-biomedical-company-25</link>
<guid isPermaLink="true">https://6ix.com/company/first-trust-germany-alphadexr-fund/news/lifeward-receives-shareholder-approval-to-close-on-strategic-partnership-with-oramedcreating-diversified-biomedical-company-25</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Positions Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed’s POD™ oral delivery technology</description>
</item>
<item>
<title>Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments</title>
<link>https://6ix.com/company/first-trust-germany-alphadexr-fund/news/barinthus-bio-reports-full-year-2025-financial-results-and-updates-on-corporate-developments-10</link>
<guid isPermaLink="true">https://6ix.com/company/first-trust-germany-alphadexr-fund/news/barinthus-bio-reports-full-year-2025-financial-results-and-updates-on-corporate-developments-10</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) to create a differentiated company focusing on clinical metabolic and autoimmune pipeline</description>
</item>
<item>
<title>Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/first-trust-germany-alphadexr-fund/news/elutia-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-43</link>
<guid isPermaLink="true">https://6ix.com/company/first-trust-germany-alphadexr-fund/news/elutia-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-43</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., March 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix</description>
</item>
<item>
<title>SEALSQ and Parrot Expand Their Strategic Partnership: Parrot to Integrate SEALSQ Post-Quantum Cryptography into Its Next Generation of Secure Drones</title>
<link>https://6ix.com/company/first-trust-germany-alphadexr-fund/news/sealsq-and-parrot-expand-their-strategic-partnership-parrot-to-integrate-sealsq-post-quantum-cryptography-into-its-next-generation-of-secure-drones-27</link>
<guid isPermaLink="true">https://6ix.com/company/first-trust-germany-alphadexr-fund/news/sealsq-and-parrot-expand-their-strategic-partnership-parrot-to-integrate-sealsq-post-quantum-cryptography-into-its-next-generation-of-secure-drones-27</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Paris, France / Geneva, Switzerland , March 13, 2026 (GLOBE NEWSWIRE) -- Parrot CEO & founder Henri Seydoux together with SEALSQ General Manager Bernard Vian</description>
</item>
<item>
<title>SBC Medical to Announce Q4 and Full‑Year 2025 Financial Results</title>
<link>https://6ix.com/company/first-trust-germany-alphadexr-fund/news/sbc-medical-to-announce-q4-and-fullyear-2025-financial-results-10</link>
<guid isPermaLink="true">https://6ix.com/company/first-trust-germany-alphadexr-fund/news/sbc-medical-to-announce-q4-and-fullyear-2025-financial-results-10</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>IRVINE, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management</description>
</item>
<item>
<title>First Andes Silver Announces New U.S. Stock Symbol</title>
<link>https://6ix.com/company/first-trust-germany-alphadexr-fund/news/first-andes-silver-announces-new-us-stock-symbol-45</link>
<guid isPermaLink="true">https://6ix.com/company/first-trust-germany-alphadexr-fund/news/first-andes-silver-announces-new-us-stock-symbol-45</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - March 13, 2026) - FIRST ANDES SILVER LTD. (TSXV: FAS) (OTC: FASLF) (FSE: 9TZ0) ("First Andes" or the "Company")</description>
</item>
<item>
<title>Purple Biotech Announces CEO Transition</title>
<link>https://6ix.com/company/first-trust-germany-alphadexr-fund/news/purple-biotech-announces-ceo-transition-11</link>
<guid isPermaLink="true">https://6ix.com/company/first-trust-germany-alphadexr-fund/news/purple-biotech-announces-ceo-transition-11</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development REHOVOT, Israel, March 13, 2026 (GLOBE</description>
</item>
<item>
<title>MicroCloud Hologram Inc. (NASDAQ: HOLO) 2025 Annual Performance Forecast: Investment Income Fluctuations Lead to Annual Loss, Core Business Maintains Steady Growth</title>
<link>https://6ix.com/company/first-trust-germany-alphadexr-fund/news/microcloud-hologram-inc-nasdaq-holo-2025-annual-performance-forecast-investment-income-fluctuations-lead-to-annual-loss-core-business-maintains-steady-growth-15</link>
<guid isPermaLink="true">https://6ix.com/company/first-trust-germany-alphadexr-fund/news/microcloud-hologram-inc-nasdaq-holo-2025-annual-performance-forecast-investment-income-fluctuations-lead-to-annual-loss-core-business-maintains-steady-growth-15</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>SHENZHEN, China, March 13, 2026 (GLOBE NEWSWIRE) -- MicroCloud Hologram Inc. (NASDAQ: HOLO), ("HOLO" or the "Company"), a technology service provider, has</description>
</item>
<item>
<title>BitFuFu to Report Full Year 2025 Financial Results on March 20, 2026</title>
<link>https://6ix.com/company/first-trust-germany-alphadexr-fund/news/bitfufu-to-report-full-year-2025-financial-results-on-march-20-2026</link>
<guid isPermaLink="true">https://6ix.com/company/first-trust-germany-alphadexr-fund/news/bitfufu-to-report-full-year-2025-financial-results-on-march-20-2026</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>SINGAPORE, March 13, 2026 (GLOBE NEWSWIRE) -- BitFuFu Inc., (“BitFuFu” or “the Company”) (NASDAQ: FUFU), a world-leading Bitcoin miner and mining services</description>
</item>
<item>
<title>P3 Health Partners Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call</title>
<link>https://6ix.com/company/first-trust-germany-alphadexr-fund/news/p3-health-partners-schedules-fourth-quarter-and-full-year-2025-earnings-release-and-conference-call-5</link>
<guid isPermaLink="true">https://6ix.com/company/first-trust-germany-alphadexr-fund/news/p3-health-partners-schedules-fourth-quarter-and-full-year-2025-earnings-release-and-conference-call-5</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>HENDERSON, Nev.--(BUSINESS WIRE)-- P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health</description>
</item>
<item>
<title>Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/first-trust-germany-alphadexr-fund/news/purple-biotech-reports-fourth-quarter-and-full-year-2025-financial-results-9</link>
<guid isPermaLink="true">https://6ix.com/company/first-trust-germany-alphadexr-fund/news/purple-biotech-reports-fourth-quarter-and-full-year-2025-financial-results-9</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Focus shifted to development of first tri-specific antibody from the CAPTN-3 platform, IM1240, targeting 5T4 tumor-associated antigen, and second tri-specific</description>
</item>
<item>
<title>Oxford Lane Capital Corp. Prices Preferred Stock Offering</title>
<link>https://6ix.com/company/first-trust-germany-alphadexr-fund/news/oxford-lane-capital-corp-prices-preferred-stock-offering-32</link>
<guid isPermaLink="true">https://6ix.com/company/first-trust-germany-alphadexr-fund/news/oxford-lane-capital-corp-prices-preferred-stock-offering-32</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>GREENWICH, Conn., March 13, 2026 (GLOBE NEWSWIRE) -- Oxford Lane Capital Corp. (Nasdaq GS: OXLC, OXLCP, OXLCL, OXLCO, OXLCZ, OXLCN, OXLCI and OXLCG) (the</description>
</item>
</channel>
</rss>